Sage Theraputic RG (SAGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sage Theraputic RG (SAGE)

SAGE 8.680

0.0%

Jul 31 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Lynn	6/13/2018 11:11:11 PM
	of 16

Analyst Actions: Canaccord Ups Sage Therapeutics Price Target to $220, Keeps at Buy - Stock Down 3.5%2:04 PM ET, 06/13/2018 - MT Newswires 02:04 PM EDT, 06/13/2018 (MT Newswires) -- Canaccord has raised its price target on Sage Therapeutics (SAGE) to $220 from $210 while keeping its buy rating, following its positive Breakthrough Therapy Meeting with the FDA on SAGE-217 for postpartum depression (PPD). "We view SAGE-217 as a potential game changer if the company successfully demonstrates that depression can be treated episodically vs. current practice that relies on chronic treatment," analyst Sumant Kulkarni said in a note. "While PPD presents unmet need, we continue to believe SAGE-217 for the MDD indication is the main stock driver and view today's developments as very encouraging." Price: 169.14, Change: -6.62, Percent Change: -3.77

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next